8-K current report · filed Nov 9, 2026

Aura Biosciences, Inc. (AURA) 8-K Current Report: November 9, 2026

Item 2.02Item 8.01Item EX-99.1Item EX-99.2AURA overview

Short answer

Aura Biosciences, Inc. (AURA) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Press release announces Aura Biosciences’ financial results for the quarter ended September 30, 2026.

Aura Biosciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces Aura Biosciences’ financial results for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed quarterly financial results and management commentary

Item 8.01 · Other Events

  • Updated corporate presentation signals refreshed investor messaging around Aura’s pipeline, strategy, and development plans
  • Company reiterates expected cash runway into the first half of 2029, a key financing-risk indicator for this clinical-stage biotech
  • Presentation likely highlights bel-sar development, including Phase 3 planning and potential ocular-oncology applications
  • Investors should review Exhibit 99.2 for specific trial milestones, data timing, funding assumptions, and strategic updates

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 CoMpass fully treated 108 participants, with topline 15-month data targeted for 2H 2027
  • FDA Special Protocol Assessment supports the planned trial design for a potential bel-sar BLA, but approval remains contingent on results
  • Cash and marketable securities $297.2M, projected runway into 1H 2029, reducing near-term financing pressure
  • Third-quarter net loss $32.1M versus $26.1M, driven by R&D expense of $24.7M and G&A expense of $10.3M
  • New CDMO relationship adds designated bel-sar manufacturing capacity, addressing a key future regulatory and commercial supply requirement

Item EX-99.2 · Exhibit EX-99.2

  • Aura’s investor presentation highlights bel-sar as a potential first vision-preserving therapy for early choroidal melanoma, an indication with approximately 11,000 annual US/EU cases
  • Phase 3 CoMpass trial fully enrolled 108 patients, with topline data expected in 2H 2027 under an FDA Special Protocol Assessment
  • Phase 2 therapeutic-regimen data showed 80% tumor control at 12 months and 90% vision preservation among phase 3-eligible patients
  • Bel-sar expansion opportunities include choroidal metastases, approximately 20,000 annual cases, and ocular surface cancers, approximately 35,000 annually
  • Expected cash runway into 1H 2029 reduces near-term financing pressure ahead of the Phase 3 readout, subject to development and regulatory risks

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aura Biosciences, Inc. 8-K filings

Get the next AURA 8-K as it lands

Follow AURA for push alerts, or ask the research agent what this filing means.